Formulations of fentanyl that use buccal, sublingual, or nasal transmucosal routes of
administration have been developed for the treatment of BTP in opioid-tolerant patients with …

Breakthrough pain (BTP) is highly prevalent (59.2%) in chronic cancer patients and normally
needs rescue treatments' with opioids when pain flares up. Transmucosal oral/nasal fentanyl …

Background Oromucosal fentanyl is currently used for the treatment of breakthrough pain
(BTP) in opioid-treated cancer patients. Ethypharm developed a sublingual formulation of …

Objective: The efficacy of intranasal fentanyl spray (INFS) was compared with that of oral
transmucosal fentanyl citrate (OTFC) for the relief of cancer-related breakthrough pain (BTP) …

Cancer patients with relatively stable chronic background pain may experience transient
episodes of pain, known as breakthrough cancer pain (BTP). There is no universally …

Fentanyl is a strong opioid analgesic, which is commonly used in the form of a transdermal
patch for the treatment of chronic cancer pain. An intranasal route of fentanyl administration …

Opioids are used to treat breakthrough cancer pain (BTCP) and can be classified by relative
duration and onset of action. Regulatory approvals of numerous transmucosal immediate …

Opioids are considered important analgesics in the treatment armamentarium for moderate-
to-severe background cancer pain. The past decade has seen clinical trials of transmucosal …

Background Breakthrough cancer pain (BTCP) is common among cancer patients and
markedly lowers their quality of life. The treatment for BTCP episodes that is recommended …

In this study we evaluated the efficacy and tolerability of sublingual fentanyl (SLF) for
breakthrough pain (BTP) in adult opioid-tolerant cancer patients. Patients received one dose …